NORTH AMERICA AND EUROPE ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) MARKET ANALYSIS

North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, by Drug Type (Oral & Parenteral Antibiotics (Vancomycin, Linezolid, Clindamycin, Ceftaroline, Daptomycin, Dalbavancin, Tedizolid, and Others) and Topical Antibiotics (Hydrogen Peroxide, Fusidic Acid, Mupirocin, Retapamulin, and Povidone-Iodine)), by Infection Type (Hospital Acquired ABSSSI and Community Acquired ABSSSI), by Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, and Europe) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Nov 2020
Code : CMI4273
Pages :252
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market - Restraints

Patent expiration of ABSSSI antibiotic drugs is a major factor restraining growth of the North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market. According to the Centers for Disease Control and Prevention, the World Health Organization, and U.S. and European governments, patent expiration leads to the production of low priced and low cost generic drugs are easily accessible which leads to their overuse and misuse. Bacteria evolve when subjected to selective pressure and multi-antibiotic resistance in organisms as ubiquitous as Escherichia coli and Staphylococcus aureus has been observed. Furthermore, patent expiry has led low cost generic drugs to dominate the market and misuse of drugs.

Restraints & Challenges: